The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Article Details
- CitationCopy to clipboard
Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst JT, Gibbs A, Kahl J, Kessler L, Lundstrom J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Bioorg Med Chem Lett. 2008 Mar 15;18(6):1772-7. doi: 10.1016/j.bmcl.2008.02.033. Epub 2008 Feb 16.
- PubMed ID
- 18325768 [ View in PubMed]
- Abstract
We have identified a novel series of potent p38 MAP kinase inhibitors through structure-based design which due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME and in vivo PK studies show these compounds to have drug-like characteristics which could result in the development of an oral treatment for inflammatory conditions.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Doramapimod Mitogen-activated protein kinase 14 IC 50 (nM) 44 N/A N/A Details Doramapimod Mitogen-activated protein kinase 14 IC 50 (nM) 17 N/A N/A Details Neflamapimod Mitogen-activated protein kinase 14 IC 50 (nM) 29 N/A N/A Details Neflamapimod Mitogen-activated protein kinase 14 IC 50 (nM) 5300 N/A N/A Details